Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ
January 29 2024 - 8:05AM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, announced its common
stock will begin trading on the NASDAQ today, Monday, January
29, 2024 at approximately 10:30 am EST under the
ticker symbol “AMIX.”
Lori Bisson, Chief Executive Officer of
Autonomix, commented, “The successful closing of our IPO and
trading on NASDAQ is a momentous milestone and the first step
toward strengthening our market position. NASDAQ provides a
platform of enhanced visibility, liquidity and expanded shareholder
base that we believe will play a key factor for the Company moving
forward. We are dedicated to dramatically improving the quality of
millions of lives by empowering the nerve-directed treatments of
tomorrow and we have positioned the Company to achieve
transformational corporate and development milestones in 2024. We
are committed to building shareholder value and look forward to
providing additional updates on our development progress.”
The Company’s catheter-based sensing technology
is being developed to do two things: sense neural signals
associated with pain or disease and precisely target those nerves
for treatment. Autonomix believes this technology is a better
alternative to the current approaches commonly used today, where
doctors either rely on systemic drugs like opioids that lose
effectiveness and have unwanted side effects or treat suspected
areas blindly in hopes of hitting the right nerves, an approach
that is often inaccurate and can miss the target and even cause
collateral damage to surrounding parts of the body.
For more information about the Company’s
technology, please visit autonomix.com.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain and pancreatitis pain, conditions that can
cause debilitating pain and need an effective solution. However,
our technology constitutes a platform with the potential to address
dozens of indications, including in cardiology, renal denervation
and chronic pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on Twitter, LinkedIn and Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Forward-looking statements in this press release
include, without limitation, the ability of Autonomix to
successfully develop its technology platform on a timely basis.
Such forward-looking statements can be identified by the use of
words such as ‘’should,‘’ ‘’may,‘’ ‘’intends,‘’ ‘’anticipates,‘’
‘’believes,‘’ ‘’estimates,‘’ ‘’projects,‘’ ‘’forecasts,‘’
‘’expects,‘’ ‘’plans,‘’ and ‘’proposes.‘’
Although Autonomix Medical, Inc. (or Autonomix)
believes that the expectations reflected in these forward-looking
statements are based on reasonable assumptions, there are a number
of risks and uncertainties that could cause actual results to
differ materially from such forward-looking statements. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading “Risk Factors” and elsewhere in the offering statement
filed with the U.S. Securities and Exchange Commission (“SEC”).
Forward-looking statements speak only as of the date of the
document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media Contact
JTC Team, LLCJenene Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From May 2024 to Jun 2024
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From Jun 2023 to Jun 2024